Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a Musan box (Sphallerocarpus gracilis) extract or a fraction thereof as an active ingredient.

The present invention discloses a mangosteen pericarp extract and process for its preparation thereof. The mangosteen pericarp extract containing α-mangostin and γ-mangostin which obtains from preparation steps comprising fragmentation, organic solvent soaking, aqueous solution, or acidic solution soaking, concentration, spray drying and grinding steps from the rind of the mangosteen. The present invention has advantages of simple preparation process to address efficiency issue, no need to have heating under reflux in extraction steps and the solvents which used are friendly to human body and environment. The mangosteen pericarp extract (α-Xones Prime) can significantly decrease insulin resistance, and bodyweight gain induced by daily high fat diet intake. In addition, administration of the mangosteen pericarp ethanolic extract can reduce fat accumulation in the adipose and muscle tissue of rats with daily high fat diet intake. The α-Xones Prime could be used as a nutraceutical ingredient for weight control or weight loss, or even prevention of metabolic syndrome and diabetes, and developed into a candidate drug composition.

The present invention relates to a pharmaceutical composition, food composition and cosmetic composition for preventing, treating, or improving allergic diseases comprising extract or fraction of a plant of the Justicia genus as an active ingredient. The extract or a fraction of a plant of the Justicia genus according to the present invention can inhibit IgE antibody secretion and the degranulation of mast cells and basophils, and exhibits an excellent anti-allergic effect, and thus can effectively prevent, treat, or improve allergic diseases.

Oxidative stress is implicated in neurodegenerative diseases such as Alzheimer's disease, and has been extensively studied as a potential target for therapeutic intervention. The present disclosure discloses a method for reducing free radicals in a mammal, the method comprises administering a composition containing an effective amount of Baillonella toxisperma extract to a mammal to reduce free radicals in the mammal. Specifically, the present disclosure demonstrates how extracts and flavonoids fractions of Baillonella toxisperma provide antioxidant and neuroprotective benefits and prevent oxidative stress in mammals.

The present invention provides a crude extract, fractions and sub-fractions from the seaweed Fucus distichus (FD), method of preparation and its use for inhibiting the growth of microbial cells, particularly bacteria causing acne or nosocomial infections such as MRSA in humans or MRSP in dogs.

A process for preparing a total extract which is a mixture of a fresh plant matter with a fatty matter includes a. contacting the fresh plant matter which comprises at least 10% of water by weight relative to its total weight before or after desiccation loss, with the fatty matter chosen from hydrogenated oil or fat at a temperature between 50° C. and 180° C.; b. grinding the plant matter-fatty matter mixture at said temperature between 50° C. to 180° C.; and c. recovering a total extract that is solid or liquid at ambient temperature with a concentration of less than or equal to 4% of water by weight relative to the total weight of the total extract. Extracts recovered from such process and treatments using the extracts are also disclosed.

Disclosed herein are pharmaceutical compositions and uses thereof in treating muscle atrophy. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

The present invention provides a composition comprising lycopene, one or both of phytoene and phytofluene, and phytosterols, wherein the concentration of lycopene is in the range of 0.3%-2% (w/w) and wherein the weight ratio of said lycopene to one or both of phytoene and phytofluene is in the range of 1:1 to 1:2.5. The invention also encompasses a method for preparing said composition.

The present invention provides a method for manufacturing fungal pharmaceutical composition, used for extracting a glycosaminoglycan fiber from a fungal cell wall. Differing from the glycosaminoglycan fiber produced by using a fabrication method proposed by Taiwan patent No. 442496 showing many drawbacks including low extraction percentage, coarse fiber, and having light-yellow color, the glycosaminoglycan fiber manufactured by using this novel method reveals the advantages of high extraction percentage, fine fibers, and showing white color. So that, the novel glycosaminoglycan fiber produced by using the present invention's method is suitable for being processed to an excipient. Moreover, because a variety of experimental results have proved that the glycosaminoglycan fiber produced by using the present invention's method possesses good adsorption ability of tissue fluid and moisture retention ability, this novel glycosaminoglycan fiber is also suitable for being processed to a skin dressing, an artificial skin, or a hydrate mask.

A method of obtaining a rutin-rich extract from a plant and a rutin-rich extract of Uncaria elliptica thus obtained.